Abstract: This invention pertains to biotechnology, more specifically to the field of human health. This document describes in particular conjugates of the SARS-CoV-2 receptor binding domain covalently conjugated to a carrier protein, the method used to obtain them, and the vaccine compositions that contain them. The vaccine compositions described in this invention are useful for the prevention of the SARS-CoV-2 infection as they induce a strong response of neutralizing antibodies.

Abstract: This invention is related to biotechnology; in particular, to the field of human health. The described vaccine compositions induce a neutralizing immune response against the SARS-CoV-2 virus. These compositions include a portion of the receptor binding protein of the SARS-Cov-2 virus, as antigen, outer-membrane vesicles of the Neisseria meningitides group B bacteria, as immunopotentiating component, and an adjuvant. The vaccine compositions that are described in this invention are useful in the prevention of infection with the SARS-CoV-2 virus.

Abstract: The present invention is related to the branches of Biotechnology and Medicine. It particularly describes highly concentrated and stable pharmaceutical formulations of the humanized monoclonal antibody nimotuzumab at a concentration within the range from 50 to 200 mg/mL. The low viscosity of these solutions allow for their administration by the subcutaneous or intramuscular routes in the treatment of cancer. These formulations are stable in both their liquid and lyophilized forms.

Abstract: A method of recovering mammalian cell clones adapted to serum and protein-free media is disclosed. The procedure includes a two-stage adaptation process to grow in that condition. A critical protein concentration interval is disclosed in which cells must grow in order to gain the capacity to survive in serum and protein-free condition, once the cells have grown at the critical interval concentrations, subsequent decreases of the concentration will affect neither viability nor cellular doubling time. The critical protein concentration interval is cell line specific. Furthermore, mammalian cells clones are disclosed, which are stable in serum- and protein-free media for at least 40 generations; additionally, clones disclosed express a recombinant product. The cell clones disclosed produce the humanized anti-EGF-R antibody hR3, the humanized anti-CD6 antibody T1hT, the chimeric anti CD3 antibody T3Q, or fragments thereof.

Abstract: The present invention relates to a method of recovering mammalian cell clones adapted to serum and protein-free media, the procedure includes a two-stage adaptation process to grow in that condition. The present invention discloses a critical protein concentration interval in which cells must grow in order to gain the capacity to survive in serum and protein-free condition, once the cells have grown at the critical interval concentrations, subsequent decreases of the concentration will affect neither viability nor cellular doubling time. The critical protein concentration interval is cell line specific. Furthermore, in the present invention mammalian cells clones are disclosed, which are stable in serum- and protein-free media for at least 40 generations; additionally, clones disclosed in the present invention express a recombinant product.